Dapagliflozin

Home > API & Intermediate > Inhibitors > Dapagliflozin Manufacturers > Dapagliflozin

Dapagliflozin

CAS NO.： 461432-26-8

FOB Price： NEGOTIABLE Get Latest Price

Specification： ≥99.5%

Documentation： Get COA after inquiry

Lead Time： 14-30 days

Max Capacity： -

Packing： 1KG/BOTTLE

Product Detail

Properties

English Name: Dapagliflozin

CAS No.: 461432-26-8

Molecular formula: C21H25ClO6

Molecular weight: 408.88

EINECS No.: 639-683-0

Boiling point: 609.0 ± 55.0 ° C (predicted)

Density: 1.349

Objective: dapagliflozin (ForxigaTM), a new antidiabetic drug developed by Bristol Myers Squibb and AstraZeneca, was approved by the European Medicines Agency (EMA) in November 12, 2012. It is the first SGLT2 inhibitor approved to be marketed for the treatment of type 2 diabetes. It can be an important choice in the treatment of diabetic drugs. It can be used as an auxiliary diet and exercise to improve blood glucose control in adults with type 2 diabetes.

Properties

Dagglitazin is a sodium glucose cotransporter 2 inhibitor (sglt2i), which is a new oral hypoglycemic drug. It can inhibit SGLT2 activity, inhibit sodium glucose reabsorption in proximal renal tubules, promote urinary glucose excretion, and reduce blood glucose concentration.

CAS No.

461432-26-8

Formula

C21H25ClO6

Molecular Mass

408.87300

Exact Mass

408.13400

PSA

99.38000

Logp

1.84440